(Q39519818)

12 September 2017

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia (English)

1 reference

12 September 2017

0 references

1 reference

C Li

1

1 reference

12 September 2017

N Narkbunnam

2

1 reference

12 September 2017

R J Samulski

3

1 reference

12 September 2017

A Asokan

4

1 reference

12 September 2017

G Hu

5

1 reference

12 September 2017

L J Jacobson

6

1 reference

12 September 2017

M J Manco-Johnson

7

1 reference

12 September 2017

P E Monahan

8

1 reference

12 September 2017

Joint Outcome Study Investigators

9

1 reference

12 September 2017

23 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

19

1 reference

12 September 2017

3

1 reference

12 September 2017

288-294

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2011.90

12 September 2017

0 references

cites work

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Adeno-associated virus vectors: potential applications for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Adeno-associated virus serotypes: vector toolkit for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Clades of Adeno-associated viruses are widely disseminated in human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Epidemiology of adenovirus-associated virus infection in a nursery population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Immune responses to adenovirus and adeno-associated virus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Improving the routine management of rheumatoid arthritis: the value of tight control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

AAV's anatomy: roadmap for optimizing vectors for translational success

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Dystrophin immunity in Duchenne's muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

inferred from DOI database lookup

7 January 2021

based on heuristic

Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.90

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/GT.2011.90

1 reference

12 September 2017

1 reference